Staph Infection

Company provides update on StaphVAX development program

Published in Medical Letter on the CDC and FDA, January 11th, 2004

Nabi Biopharmaceuticals (NABI) has continued to advance the development of StaphVAX (Staphylococcus aureus polysaccharide conjugate vaccine) and announced updates to its manufacturing and clinical trial plans.

Currently in a confirmatory phase III clinical trial, StaphVAX is the company's investigational vaccine that is designed to prevent Staphylococcus aureus blood stream infections.

Nabi Biopharmaceuticals continues to make progress towards the manufacture of StaphVAX consistency lots at Cambrex Bio Science, Inc., to support the license application with the European Union planned for the end of 2004.

Capacity at...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2004-01-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry